Global demand for GLP 1 weight loss medicines continues to surge, yet pharmaceutical companies are finding it increasingly difficult to promote their products because of strict advertising regulations in many countries.

According to CNN, in a report by Anna Cooban, major drug manufacturers such as Novo Nordisk and Eli Lilly are adopting increasingly creative approaches to raise public awareness of obesity without directly promoting their prescription medicines. The restrictions are particularly stringent outside the United States and New Zealand, the only developed countries that broadly permit direct to consumer advertising of prescription drugs.

In the United Kingdom, Novo Nordisk recently sponsored an interactive public exhibition highlighting the challenges faced by people living with obesity. While the company’s branding was visible throughout the event, no specific medicines were promoted, reflecting regulations that prohibit the public advertising of prescription treatments.

Industry experts say the explosive commercial success of GLP 1 medicines has created a highly competitive market, encouraging companies to invest heavily in disease awareness campaigns that remain within legal boundaries. At the same time, regulators are increasing scrutiny of promotional practices, particularly those involving online pharmacies and compounded versions of weight loss medicines.

The United States Food and Drug Administration has issued warning letters to several telehealth companies over advertisements that allegedly misrepresented compounded GLP 1 products as being approved by the regulator. Such actions underline growing concerns about misleading marketing as demand continues to rise.

The evolving regulatory landscape highlights the delicate balance pharmaceutical companies must maintain between educating the public, complying with advertising laws and competing in one of the world’s fastest growing healthcare markets.